MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
June 25, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., June 25, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
February 05, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
November 15, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
November 01, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
October 31, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
October 16, 2023 16:00 ET
|
MBX Biosciences, Inc.
MBX 2109 was generally well-tolerated across all dosing cohorts MBX 2109 pharmacokinetics reflected the intended prodrug design and support once-weekly dosing MBX 2109 increased albumin adjusted...
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
October 09, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
October 03, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 03, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...